Without recovery (N = 20) With recovery (N = 20)
P value
Age (y/o) 59.7 ± 14.6 50.8 ± 14.3 0.059
Male (n, %) 18 (90.0%) 14 (70.0%) 0.235
Hypertension (n, %) 3 (15.0%) 3 (15.0%) 1.000
Diabetes (n, %) 2 (10.0%) 1 (5.0%) 1.000
Medication before ablation
Beta blocker or CCB only (n, %) 7 (35.0%) 8 (40.0%) 1.000
Class I AAD (n, %) 8 (40.0%) 5 (25.0%) 0.501
Amiodarone (n, %) 5 (25.0%) 7 (35.0%) 0.731
Presence of Sustained VT (n, %) 9 (45.0%) 3 (15.0%) 0.082
Presence of Non-Sustained VT (n, %) 5 (25.0%) 4 (20.0%) 1.000
PVC burden (pre-ablation) (beats/day) 21267 ± 10968 19760 ± 14266 0.759
PVC burden (pre-ablation) (%)* 19.5 ± 9.3 19.8 ± 14.3 0.948
Ejection fraction (pre-ablation) (%)* 34.3 ± 7.3 40.7 ± 10.1 0.027
VA morphology
RBBB morphology (n,%) 10 (50.0%) 9 (45.0%) 1.000
Coupling interval 522.0 ± 75.6 499.0 ± 55.3 0.278
QRSd, ms 178.3 ± 23.1 149.0 ± 24.9 <0.001
IDT, ms 64.7 ± 24.3 63.0 ± 19.9 0.815
PdW, ms 57.4 ± 20.5 62.5 ± 20.5 0.432
Q-wave aVL/aVR ratio 1.55 ± 0.43 1.44 ± 0.36 0.376
MDI 0.44 ± 0.13 0.48 ± 0.12 0.271
Earliest activation before VA (ms) -41.2 ± 10.2 -40.5 ± 24.2 0.906
Successful ablation site (n, %)
ASV 5 (25.0%) 6 (30.0%) 1.000
Subvalvular 6 (30.0%) 2 (10.0%) 0.235
GCV/AIV 7 (35.0%) 8 (40.0%) 1.000
Epicardium 2 (10.0%) 4 (20.0%) 0.661
Multiple site ablation requirement (n, %) 14 (70.0%) 8 (40.0%) 0.111
AEAD 16.3±8.6 16.3±7.9 0.985
Acute procedural success (n, %) 18 (90.0%) 17 (85.0%) 1.000
PVC recurrence (n, %) 10 (50.0%) 3 (15.0%) 0.041